 Connection
Virginia Borges to Antineoplastic Agents, Hormonal
This is a "connection" page, showing publications Virginia Borges has written about Antineoplastic Agents, Hormonal.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.747 |
|
|
|
-
Borges VF. Options for Endocrine-Refractory, Hormone Receptor-Positive Breast Cancer: Which Target and When? J Clin Oncol. 2021 12 10; 39(35):3890-3896.
Score: 0.687
-
Kabos P, Borges VF. Fulvestrant: a unique antiendocrine agent for estrogen-sensitive breast cancer. Expert Opin Pharmacother. 2010 Apr; 11(5):807-16.
Score: 0.308
-
Come SE, Borges VF. Role of fulvestrant in sequential hormonal therapy for advanced, hormone receptor-positive breast cancer in postmenopausal women. Clin Breast Cancer. 2005 Apr; 6 Suppl 1:S15-22.
Score: 0.218
-
Wassermann J, Gelber SI, Rosenberg SM, Ruddy KJ, Tamimi RM, Schapira L, Borges VF, Come SE, Meyer ME, Partridge AH. Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer. Cancer. 2019 09 15; 125(18):3266-3274.
Score: 0.145
-
Ruddy KJ, DeSantis SD, Barry W, Guo H, Block CC, Borges V, Winer EP, Partridge AH. Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen. Clin Breast Cancer. 2014 Dec; 14(6):413-6.
Score: 0.103
-
Urquhart A, Borges V, Rabinovitch R, Singh M, Robinson W, Seligman P, Arya J, Finlayson C, Elias A. A postmenopausal woman with early-stage breast cancer and borderline hormone-receptor staining. Oncology (Williston Park). 2005 Mar; 19(3):278, 283-4, 287 passim.
Score: 0.054
-
Azim HA, Niman SM, Partridge AH, Demeestere I, Ruggeri M, Colleoni M, Saura C, Shimizu C, Saetersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Ru?z-Borrego M, Moore HCF, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Klar NJ, Spanic T, Ruddy K, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, Peccatori FA. Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy. J Clin Oncol. 2024 Aug 10; 42(23):2822-2832.
Score: 0.051
-
Rosenberg SM, Zheng Y, Gelber S, Ruddy KJ, Poorvu P, Sella T, Tamimi RM, Wassermann J, Schapira L, Borges VF, Come S, Peppercorn J, Sepucha KR, Partridge AH. Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancer. Breast Cancer Res Treat. 2023 Feb; 197(3):547-558.
Score: 0.046
-
Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA, Colleoni M, Saura C, Shimizu C, S?tersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Borrego MR, Moore HC, Saunders C, Cardoso F, Susnjar S, Bjelic-Radisic V, Smith KL, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O. Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. Breast. 2021 Oct; 59:327-338.
Score: 0.042
-
Poorvu PD, Gelber SI, Zheng Y, Ruddy KJ, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Lambertini M, Rosenberg SM, Partridge AH. Pregnancy after breast cancer: Results from a prospective cohort of young women with breast cancer. Cancer. 2021 04 01; 127(7):1021-1028.
Score: 0.040
-
von Hippel C, Rosenberg SM, Austin SB, Sprunck-Harrild K, Ruddy KJ, Schapira L, Come S, Borges VF, Partridge AH. Identifying distinct trajectories of change in young breast cancer survivors' sexual functioning. Psychooncology. 2019 05; 28(5):1033-1040.
Score: 0.036
-
Brooks G, Borges V, Singh M, Rabinovitch R, Finlayson C, Elias A. A perimenopausal woman with a small, ER/HER2-positive, node-negative breast cancer. Oncology (Williston Park). 2008 Oct; 22(11):1270-6.
Score: 0.017
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|